Japanese recommendation moves alogliptin closer to the market
This article was originally published in Scrip
Executive Summary
An advisory committee to Japan's ministry of health, labour and welfare has recommended for approval Takeda's oral antidiabetic, alogliptin. The positive opinion moves the DPP-4 inhibitor closer to what is likely to be its first market, following the delays in the US last year. Alogliptin has yet to be filed in Europe.